Literature DB >> 27792585

Comparison of Detection Rate and Mutational Pattern of Drug-Resistant Mutations Between a Large Cohort of Genotype B and Genotype C Hepatitis B Virus-Infected Patients in North China.

Xiaodong Li1, Yan Liu1, Shaojie Xin2, Dong Ji2, Shaoli You2, Jinhua Hu2, Jun Zhao2, Jingjing Wu1, Hao Liao1, Xin-Xin Zhang3, Dongping Xu1.   

Abstract

The study aimed to investigate the association of prevalent genotypes in China (HBV/C and HBV/B) with HBV drug-resistant mutations. A total of 13,847 nucleos(t)ide analogue (NA)-treated patients with chronic HBV infection from North China were enrolled. HBV genotypes and resistant mutations were determined by direct sequencing and confirmed by clonal sequencing if necessary. HBV/B, HBV/C, and HBV/D occupied 14.3%, 84.9%, and 0.8% across the study population, respectively. NA usage had no significant difference between HBV/B- and HBV/C-infected patients. Lamivudine-resistant mutations were more frequently detected in HBV/C-infected patients, compared with HBV/B-infected patients (31.67% vs. 25.26%, p < 0.01). Adefovir- and entecavir-resistant mutation detection rates were similar, but the mutational pattern was different between the two genotypes. For adefovir-resistant mutations, HBV/C-infected patients had a higher detection rate of rtA181 V (HBV/C 5.29% vs. HBV/B 1.36%, p < 0.01) and a lower detection rate of rtN236T (2.70% vs. 6.54%, p < 0.01). For entecavir-resistant mutations, HBV/C-infected patients had a higher detection rate of rtM204 V/I+T184 substitution or S202G/C (3.66% vs. 2.16%, p < 0.01) and a lower detection rate of rtM204 V/I+M250 V/I/L substitution (0.67% vs. 1.46%, p < 0.01). Multidrug-resistant mutations (defined as coexistence of mutation to nucleoside and nucleotide analogues) were detected in 104 patients. HBV/C-infected patients had a higher detection rate of multidrug-resistant mutation than HBV/B-infected patients (0.83% vs. 0.35%, p < 0.05). The study for the first time clarified that HBV/C-infected patients had a higher risk to develop multidrug-resistant mutations, compared with HBV/B-infected patients; and HBV/C- and HBV/B-infected patients had different inclinations in the ETV-resistant mutational pattern.

Entities:  

Keywords:  drug resistance; genotype; hepatitis B virus

Mesh:

Substances:

Year:  2016        PMID: 27792585     DOI: 10.1089/mdr.2016.0093

Source DB:  PubMed          Journal:  Microb Drug Resist        ISSN: 1076-6294            Impact factor:   3.431


  5 in total

1.  Evolution of drug-resistant mutations in HBV genomes in patients with treatment failure during the past seven years (2010-2016).

Authors:  Hong-Yu Zhang; Long-Gen Liu; Chun-Yan Ye; Chun-Hua Chen; Shuang-Xiong Hang; Zhen Zhu; Hong-Yu Shen; Ze-Yu Huang; Wen-Yi Chen; Yuan Xue
Journal:  Virus Genes       Date:  2017-11-08       Impact factor: 2.332

2.  Global prevalence and phylogeny of hepatitis B virus (HBV) drug and vaccine resistance mutations.

Authors:  Jolynne Mokaya; Tetyana I Vasylyeva; Eleanor Barnes; M Azim Ansari; Oliver G Pybus; Philippa C Matthews
Journal:  J Viral Hepat       Date:  2021-05-07       Impact factor: 3.517

3.  Molecular Epidemiological Characteristics and Risk Factors for Acquiring HBV Among Li Ethnic in Baisha County, Hainan Island-Subgenotype D3 Was First Discovered in China.

Authors:  Ru Xu; Dandan Song; Min Wang; Jieting Huang; Qiao Liao; Zhengang Shan; Xia Rong; Yongshui Fu
Journal:  Front Microbiol       Date:  2022-02-07       Impact factor: 5.640

4.  Effect of mutations across reverse transcriptase region on HBV replication and progression of liver diseases in Chinese patients.

Authors:  Xiaoqin Lai; Wenfa Chen; Yuzhu Wu; Yali Gao; Yalan Zhang; Xuwei Xu; Ya Fu; Xinwen Wang; Yanbing Yang; Yin Zhang
Journal:  J Clin Lab Anal       Date:  2022-06-03       Impact factor: 3.124

5.  Mutational characterization of HBV reverse transcriptase gene and the genotype-phenotype correlation of antiviral resistance among Chinese chronic hepatitis B patients.

Authors:  Ya Fu; Songhang Wu; Yuhai Hu; Tianbin Chen; Yongbin Zeng; Can Liu; Qishui Ou
Journal:  Emerg Microbes Infect       Date:  2020-12       Impact factor: 7.163

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.